focus -WSS

focus

author：comprehensive 2025-10-03 00:07:39 - browse：7

Becton Dickinson plans to pay $4.2 billion for Edwards Lifesciences’ critical care business, which sells technology that monitors the heart conditions of critically ill patients.

Edwards had told investors in December 2023 that it planned to spin off the business in order to focus more sharply on addressing structural defects in the heart. BD, meanwhile, wants to increase its monitoring presence in hospitals. In a statement announcing the acquisition, the company touted the “advanced AI algorithms” used in Edwards’ monitors.

BD CEO Tom Polen said in a statement that the acquisition will bolster BD’s portfolio of “AI-enabled clinical decision tools” and digital health products in general.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Kellogg’s is going to war over Mexico’s nutrition label rules

Wikipedia

WSS

Intellia plays down concerns on accidental germline transmission

Intellia plays down concerns on accidental germline transmission

Wegovy improves function in certain heart failure patients

STAT Summit: Meghan O’Rourke on making chronic illness visible

STAT Readout Newsletter: Biotech news today

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

explore

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

New air purifier tech could be key to improving indoor air quality

Health officials lay out plans to cope with respiratory virus season

In Memoriam: Notable people who died in 2023

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Dobbs anniversary: the lost opportunity of abortion as health care

FDA advisory panel to debate high blood pressure devices

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

National associations that represent hospice owe an apology

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

California store owner shot dead in dispute over displaying Pride flag: Police

knowledge

Kellogg’s is going to war over Mexico’s nutrition label rules

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Roche's accidental data boosts hopes for anti

Roche acquires Telavant from Roivant, adding experimental IBD treatment

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Wikipedia

Wikipedia

hotspot

entertainment